Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: A pilot study.

José Luis Gálvez-Romero O Palmeros-RojasF A Real-RamírezS Sánchez-RomeroR Tome-MaxilM P Ramírez-SandovalR Olivos-RodríguezS E Flores-EncarnaciónA A Cabrera-EstradaJ Ávila-MoralesV Cortés-SánchezG Sarmiento-PadillaS E Tezmol-RamírezD Aparicio-HernándezM I Urbina-SánchezM Á Gómez-PlumaS Cisneros-MéndezD I Rodríguez-RivasS Reyes-InurrigarroG Cortés-DíazC Cruz-DelgadoJ Navarro-GonzálezJ Deveaux-HomsSigifredo Pedraza-Sánchez

Published in: Journal of internal medicine (2021)

CsA used as an adjuvant to steroid treatment for COVID-19 patients showed to improve outcomes and reduce mortality, mainly in those with moderate to severe disease. Further investigation through controlled clinical trials is warranted.

Keyphrases

low dose
clinical trial
sars cov
coronavirus disease
early stage
randomized controlled trial
type diabetes
metabolic syndrome
cardiovascular events
risk factors
cardiovascular disease
coronary artery disease
weight loss
drug induced
open label
double blind